187 completed, 15 terminated, 11 unknown, 11 withdrawn. 247 Phase 2, 71 Phase 1, 35 Phase 3.
Follow Malaria: new trials by email Literature Review of Malaria trials Research Report on Malaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria SJ733/TQ placebo, CQ/TQ Placebo, CQ/TQ - Malaria, Malaria Vivax | Phase 2 | Not yet recruiting | R. Kiplin Guy | 104 | 2026-12-01 | 2026-10-21 |
| Transmission-Blocking Vaccine Pvs230D1-EPA/Matrix-M in Healthy Malaria-Naive Adults Using a Plasmodium Vivax Controlled Human Malaria Infection and Transmission Model Plasmodium vivax Challenge Agent Derived from PvHMB-CCE001, Pvs230D1-EPA/Matrix-M - Healthy Volunteers, Malaria | Phase 1 / Phase 2 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 220 | 2026-11-17 | 2026-11-12 |
| A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria GSK3772701 600 mg, GSK3772701 900 mg, GSK3772701 150 mg - Malaria, Falciparum | Phase 2 | Recruiting | GlaxoSmithKline | 70 | 2026-10-07 | 2026-11-10 |
| Tafenoquine Drug Levels in Small Children Chloroquine, Tafenoquine - Plasmodium Vivax Malaria, Vivax Malaria | Phase 2 | Not yet recruiting | University of Oxford | 20 | 2026-09-01 | 2026-09-22 |
| PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali PfSPZ-LARC2 Vaccine, Normal Saline - Malaria (Plasmodium Falciparum) | Phase 2 | Recruiting | Sanaria Inc. | 300 | 2026-07-20 | 2026-07-23 |
| Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults Genetically attenuated PfSPZ Vaccine, Normal Saline (0.9% Sodium Chloride) - Malaria (Plasmodium Falciparum) | Phase 2 | Recruiting | Sanaria Inc. | 180 | 2026-05-04 | 2026-06-01 |
| Postpartum 8-aminoquinoline Breast Milk Study Daily primaquine (0.5 mg/kg per day) for 14 days given with food food and water, Daily primaquine 1 mg/kg per day for 7 days given with food and water, Single-dose tafenoquine given with food and water to prevent gastrointestinal discomfort - Drug Pharmacokinetics in Healthy Volunteers | Phase 2 / Phase 3 | Not yet recruiting | Curtin University | 60 | 2026-04-01 | 2026-03-18 |
| L9LS-R21 Interaction Single dose of 1800 mg L9LS SC (12mL), Placebo 12 mL SC, Single dose of 225 mg L9LS SC (1.5mL) - Malaria | Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-03-01 | 2026-04-09 | |
| Dose Finding Trial of R21/Matrix-M in School Children 5µg R21/50µg Matrix-M, 10µg R21/50µg Matrix-M - Malaria (Plasmodium Falciparum) | Phase 2 | Active not recruiting | University of Oxford | 40 | 2026-02-18 | 2026-08-24 |
| Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2) KAE609, SoC (Coartem), KLU156 - Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | Recruiting | Novartis Pharmaceuticals | 120 | 2026-02-12 | 2026-10-15 |
| Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria Artemether lumefantrine tablets, Artemether Lumefantrine and Imatinib Mesylate - Malaria (Plasmodium Falciparum) | Phase 2 | Recruiting | Victoria Biomedical Research Institute | 1116 | 2026-01-20 | 2026-06-29 |
| Phase IIa/b Trial of PvCS/Montanide ISA-51 Malaria Vaccine in Adults in Chocó, Colombia PvCS/Montanide ISA-51 VG Vaccine, Placebo - Montanide ISA-51 VG Adjuvant Alone - Plasmodium Vivax Malaria, Plasmodium Vivax Infection | Phase 2 | Not yet recruiting | Malaria Vaccine and Drug Development Center | 72 | 2026-01-19 | 2026-01-28 |
| A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M R21, RH5.1, R78C - Malaria,Falciparum | Phase 2 | Active not recruiting | University of Oxford | 360 | 2025-12-15 | 2026-10-21 |
| Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1) KAE609 (Cipargamin), SoC (Coartem), INE963 - Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | Completed | Novartis Pharmaceuticals | 95 | 2025-10-10 | 2026-09-10 |
| A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months RTS,S/AS01E vaccine - Malaria | Phase 2 | Recruiting | GlaxoSmithKline | 238 | 2025-08-06 | 2025-09-29 |
| L9LS in Women of Childbearing Potential in Mali Single dose of 1800 mg L9LS SC, Placebo - Malaria | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 279 | 2025-07-22 | 2026-10-30 |
| Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M Adjuvant Pfs25-IMX313, Pfs48/45 - Plasmodium Falciparum Malaria | Phase 1 / Phase 2 | Active not recruiting | University of Oxford | 56 | 2025-07-07 | 2026-02-23 |
| Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults Pyronaridine Tetraphosphate, Artesunate Drug Combination, PfSPZ Challenge (NF54), MVA ME-TRAP - Malaria | Phase 1 / Phase 2 | Not yet recruiting | University Hospital Tuebingen | 30 | 2025-06-01 | 2024-12-06 |
| Infant Malaria Vaccine Schedule Optimization R21 Matrix-M (R21/MM) Malaria Vaccine, Placebo, Hexavalent Vaccine - Malaria Vaccines, Malaria (Plasmodium Falciparum) | Phase 2 | Active not recruiting | PATH | 975 | 2025-05-30 | 2026-09-29 |
| Plasmodium Immunotherapy for Advanced Ovarian Cancer Plasmodium immunotherapy - Advanced Ovarian Cancer | Phase 2 / Phase 3 | Not yet recruiting | CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd. | 30 | 2024-07-20 | 2024-07-22 |
Showing 20 of 247. Sign in to see all of them.
Malaria, Falciparum (108) · Malaria, Vivax (29) · Malaria, Cerebral (5) · Parasitic Diseases (5) · Acute malaria (3) · Glucosephosphate Dehydrogenase Deficiency (3) · Parasitemia (3) · Seizures (3) · Adenoviridae Infections (2) · Coccidiosis (2) · Epilepsy (2) · Fever (2) · Infections (2) · Recurrence (2)
Mosquito-Borne Diseases (247) · Protozoan Infections (246) · Vector Borne Diseases (246) · Infections (245) · Parasitic Diseases (242) · Pathological Conditions, Signs and Symptoms (10) · Hemic and Lymphatic Diseases (8) · Nervous System Diseases (7) · Central Nervous System Diseases (6) · Central Nervous System Infections (6) · Pathologic Processes (6) · Central Nervous System Parasitic Infections (5) · Central Nervous System Protozoal Infections (5) · Hematologic Diseases (5)
Artemether, Lumefantrine Drug Combination (22) · Primaquine (22) · Chloroquine (18) · fanasil, pyrimethamine drug combination (16) · Artesunate (15) · Amodiaquine (14) · Azithromycin (12) · Saline Solution (11) · tafenoquine (11) · NITD 609 (8) · RTS malaria vaccine (8) · Rabies Vaccines (8) · piperaquine (8) · pyronaridine tetraphosphate, artesunate drug combination (7) · Matrix-M (6)
University of Oxford (38) · London School of Hygiene and Tropical Medicine (21) · GlaxoSmithKline (20) · U.S. Army Medical Research and Development Command (18) · National Institute of Allergy and Infectious Diseases (NIAID) (14) · Medicines for Malaria Venture (13) · Novartis Pharmaceuticals (13) · Pfizer (7) · Sanaria Inc. (7) · Heidelberg University (6) · Malaria Vaccine and Drug Development Center (5) · Radboud University Medical Center (5) · University of California, San Francisco (4) · Jomaa Pharma GmbH (3) · Sanofi (3)
Burkina Faso (35) · Mali (30) · Kenya (29) · United States (22) · Gabon (21) · United Kingdom (19) · Thailand (17) · Uganda (13) · Ghana (12) · Mozambique (10) · Tanzania (10) · Colombia (8) · Côte d’Ivoire (8) · Democratic Republic of the Congo (8) · The Gambia (8)
Kassoum Kayentao, MD, MPH, PhD (5) · Adrian VS Hill, D.Phil, FRCP (4) · James McCarthy, Prof (4) · Adrian V S Hill, MD (3) · Brian Greenwood, FRCP, FRS (3) · Patrick E Duffy, M.D. (3) · Peter Crompton, MD, MPH (3) · Adrian V Hill, DPhill FRCP (2) · Adrian VS Hill, MA, BM BCh, DPhil, DM (2) · Alassane Dicko (2) · Alassane Dicko, MD (2) · Daniel Chandramohan, MBBS, PhD (2)
PMID 39377226, PMID 28495354, PMID 21443960, PMID 23433102, PMID 23899517, PMID 23962071, PMID 25211344, PMID 26292027, PMID 26292257, PMID 27695088, PMID 28472957, PMID 29324864, PMID 31672143, PMID 34179977, PMID 35664997, PMID 36875126, PMID 41176969, PMID 10190913, PMID 10501745, PMID 11832638, PMID 12011004, PMID 12663340, PMID 15069048, PMID 15838784, PMID 16338450, PMID 16503464, PMID 16904798, PMID 17213921, PMID 17442466, PMID 17707447, PMID 18231580, PMID 18270560, PMID 18286187, PMID 18320064, PMID 18419347, PMID 18545693, PMID 18694333, PMID 18752443, PMID 19098989, PMID 19262754, PMID 19365567, PMID 19390585, PMID 19415120, PMID 19517101, PMID 19569964, PMID 19569965, PMID 19630971, PMID 19641203, PMID 19649245, PMID 19673614
2015 (2), R01NS074409 (2), 2014 (1), 2016 (1), R01HL086488 (1), R01NS102176 (1), U01AI065683 (1), U01AI195203 (1)